fda changes semaglutide What Patients Need to Know About the GLP-1 Policy Important Update: Changes to Compounded

Our findings suggest that we can repurpose GLP-1 agonists as potent anti-hyperalgesic and anti-inflammatory drugs to treat neuropathic pain without serious side effects

Eight other applications for generic semaglutide are already under review by the regulator

It's the foundation upon which all good data is built

Jul 2023;36(4):316-322

Medical Management : For patients with documented osteoporosis or high fracture risk, pharmacologic bone-protective therapy may be indicated regardless of GLP-1 use

Haematuria with pain, fever, or difficulty urinating may indicate a urinary tract infection, kidney stones, or other urological conditions requiring assessment